NasdaqCM - BOATS Real Time Price USD

Jasper Therapeutics, Inc. (JSPR)

0.5202 -0.0118 (-2.22%)

At close: October 30 at 4:00:01 PM EDT

0.5200 -0.0002 (-0.04%)

Overnight: 1:28:26 AM EST

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for JSPR

Chart does not reflect overnight price.

Previous Close 0.5320
Open 0.5160
Bid 0.4083 x 200
Ask 0.7234 x 200
Day's Range 0.5106 - 0.5539
52 Week Range 0.3150 - 2.4200
Volume 396,127
Avg. Volume 496,181
Market Cap (intraday) 17.309M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -1.0400
Earnings Date (est.) Nov 10, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 20.00
Zacks Rating Bullish

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.

jaspertx.com

Full Time Employees

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

JSPR

71.57%

S&P 500 (^GSPC)

10.73%

1-Year Return

JSPR

76.14%

S&P 500 (^GSPC)

11.11%

3-Year Return

JSPR

92.69%

S&P 500 (^GSPC)

81.91%

5-Year Return

JSPR

99.43%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q4 FY24

Revenue --

Earnings -24.32M

Profit Margin 0.00%

FY24

-20M

-15M

-10M

-5M

0.0%

Analyst Price Targets

20.00

20.00 Average

0.5202 Current

20.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 8/12/2026

Analyst Piper Sandler

Rating Action Initiated

Rating Overweight

Price Action Announces

Price Target 2

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

--
Diluted EPS (ttm)

-1.0400

Balance Sheet and Cash Flow

Total Cash (mrq)

--
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

--

ENSC Ensysce Biosciences, Inc.

0.4210 -3.88%

PALI Palisade Bio, Inc.

1.1600 -2.52%

KTTA Pasithea Therapeutics Corp.

0.3702 +0.16%

KPRX Kiora Pharmaceuticals, Inc.

1.5600 -11.36%

CNTX Context Therapeutics Inc.

0.1891 -6.25%

U.S. markets open in 6h 14m

Jasper Therapeutics, Inc. (JSPR)

2.00%

-10.31%

-44.42%

-71.57%

-76.14%

-99.43%

-99.47%

Jasper Therapeutics, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch